{"id":"risankizumab-risa","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL3990029","moleculeType":"Antibody"},"_dailymed":{"setId":"7148c8eb-b39e-e20a-6494-a6df82392858","title":"SKYRIZI (RISANKIZUMAB-RZAA) KIT SKYRIZI (RISANKIZUMAB-RZAA) INJECTION [ABBVIE INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-23 is a key driver of inflammatory responses in immune-mediated diseases. By blocking the p19 subunit of IL-23, risankizumab prevents IL-23 signaling and reduces the differentiation and activation of pro-inflammatory T cells, particularly Th17 cells. This leads to decreased inflammation in conditions like psoriasis and inflammatory bowel disease.","oneSentence":"Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:48:06.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT07448402","phase":"","title":"Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Psoriasis, Psoriasis Arthritis, Psoriasis (PsO)","enrollment":50},{"nctId":"NCT06249555","phase":"","title":"VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study","status":"RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2024-03-20","conditions":"Crohn's Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Skyrizi"],"phase":"marketed","status":"active","brandName":"Risankizumab (RISA)","genericName":"Risankizumab (RISA)","companyName":"Caja Costarricense de Seguro Social","companyId":"caja-costarricense-de-seguro-social","modality":"Biologic","firstApprovalDate":"","aiSummary":"Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. Used for Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}